Valuation: argenx SE

Market Cap 47.78B 54.54B 44.08B 40.7B 77.17B 5,203B 78.42B 527B 206B 2,566B 205B 200B 8,819B P/E 2026 *
32.7x
P/E 2027 * 25.1x
Enterprise Value 43.12B 49.22B 39.78B 36.73B 69.65B 4,695B 70.77B 475B 186B 2,316B 185B 181B 7,959B EV / Sales 2026 *
8.29x
EV / Sales 2027 * 6.47x
Free-Float
99.98%
Yield 2026 *
0.06%
Yield 2027 * 0.11%

Last Transcript: argenx SE

1 day-4.14%
1 week-8.06%
Current month-5.87%
1 month+0.10%
3 months+11.99%
6 months+10.12%
Current year+6.56%
1 week 760.6
Extreme 760.6
832
1 month 743.2
Extreme 743.2
833.6
Current year 568.4
Extreme 568.4
833.6
1 year 477.1
Extreme 477.1
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.07
Extreme 12.07
833.6
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap.
11-23Fiscal year

Director

4,680 0.0076%
11-23Fiscal year

Chief Executive Officer

2,000 0.0032%
11-23Sell

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
-4.16%+1.63%+70.58%+143.85% 12.37B
Average -1.02%-0.09%+55.93%+148.15% 25.36B
Weighted average by Cap. -1.07%-1.31%+55.80%+138.10%

Financials

2026 *2027 *
Net sales 5.2B 5.94B 4.8B 4.43B 8.41B 567B 8.54B 57.38B 22.49B 279B 22.3B 21.81B 961B 6.35B 7.25B 5.86B 5.41B 10.26B 691B 10.42B 70.02B 27.44B 341B 27.21B 26.62B 1,172B
Net income 1.51B 1.72B 1.39B 1.29B 2.44B 164B 2.48B 16.66B 6.53B 81.12B 6.47B 6.33B 279B 2.08B 2.37B 1.91B 1.77B 3.35B 226B 3.41B 22.88B 8.97B 111B 8.89B 8.7B 383B
Net Debt -4.66B -5.32B -4.3B -3.97B -7.53B -507B -7.65B -51.37B -20.13B -250B -19.96B -19.53B -860B -6.72B -7.67B -6.2B -5.72B -10.85B -732B -11.03B -74.08B -29.03B -361B -28.78B -28.16B -1,240B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
10/07/26 €763.80 -4.14% 83,016
09/07/26 €796.80 -0.38% 95,255
08/07/26 €799.80 -1.53% 88,947
07/07/26 €812.20 -0.10% 89,340
06/07/26 €813.00 -2.14% 66,127
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
763.80EUR
Average target price
886.67EUR
Spread / Average Target
+16.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock